Esperion Therapeutics Dividend
Dividend criteria checks 0/6
Esperion Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.2% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$0.46 |
Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
May 20A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Feb 28Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Jan 22Esperion Is Sitting On A Potential Blockbuster Drug
Jan 14Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Jun 19Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts
Mar 09Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%
Feb 23Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol
Aug 26Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings
Aug 09Esperion Therapeutics Q2 2022 Earnings Preview
Aug 01Esperion Therapeutics: 2021 Labors Paying Off In 2022
May 07Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout
Feb 24Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022
Jan 20Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection
Oct 27Esperion: Hunting Big Game In The Danger Zone
Aug 05Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year
May 09Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 04Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.
Dividend Yield vs Market
Esperion Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (ESPR) | n/a |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.4% |
Industry Average (Pharmaceuticals) | 2.2% |
Analyst forecast in 3 Years (ESPR) | 0% |
Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ESPR's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ESPR has not reported any payouts.